South London Cardiovascular Guidance (subject to local CCG approval)

  • Acute Coronary Syndrome - Rivaroxaban
  • Antiplatelet options
  • Chronic heart failure
  • Chronic stable angina
  • Creatinine Clearance
  • Hypertension management
  • Lipid management
  • Statin guidelines
  • Stroke prevention in Atrial Fibrillation (AF) - DOACs
  • Venous thromboembolism (VTE) - DOACs
  • Oral anticoagulation card - information leaflet

Coronavirus Pandemic: Guidance for the Safe Switching of Warfarin to Direct Oral Anticoagulants (DOACs) for Patients with Non-Valvular AF and Venous Thromboembolism (DVT / PE) can be found here


 

​​

  
  
ACUTE CORONARY SYNDROME - Notification of Initiation Rivaroxaban 2016.docxACUTE CORONARY SYNDROME - Notification of Initiation Rivaroxaban 2016
ACUTE CORONARY SYNDROME - Rivaroxaban prescribing guidance 2016.docxACUTE CORONARY SYNDROME - Rivaroxaban prescribing guidance 2016
ACUTE CORONARY SYNDROME - Rivaroxaban prescribing guidance 2016.pdfACUTE CORONARY SYNDROME - Rivaroxaban prescribing guidance 2016
ACUTE CORONARY SYNDROME - Rivaroxaban Transfer of care April 2016.docxACUTE CORONARY SYNDROME - Rivaroxaban Transfer of care April 2016
ANGINA chronic stable - Ivabradine guideline March 2016.pdfANGINA chronic stable - Ivabradine guideline March 2016
ANGINA Chronic Stable - Medical Therapy algorithm v2 March 17.pdfANGINA Chronic Stable - Medical Therapy algorithm v2 March 17
ANTIPLATELET - Summary of antiplatelet options in cardiovascular disease final V2.pdfANTIPLATELET - Summary of antiplatelet options in cardiovascular disease final V2
Calculating renal function for DOACs Jan 2020 v2 SWL.pdfCalculating renal function for DOACs Jan 2020 v2 SWL
HEART FAILURE - Pharmacological Management of Heart Failure.pdfHEART FAILURE - Pharmacological Management of Heart Failure
HEART FAILURE chronic - Ivabradine guideline March 2016.pdfHEART FAILURE chronic - Ivabradine guideline March 2016
HEART FAILURE chronic symptomatic - Sacubitril valsartan Notification of initiation 2016.docxHEART FAILURE chronic symptomatic - Sacubitril valsartan Notification of initiation 2016
HEART FAILURE chronic symptomatic - Sacubitril valsartan prescribing guidance 2016.pdfHEART FAILURE chronic symptomatic - Sacubitril valsartan prescribing guidance 2016
HEART FAILURE chronic symptomatic - Sacubitril valsartan Transfer of Care 2016.docxHEART FAILURE chronic symptomatic - Sacubitril valsartan Transfer of Care 2016
HYPERCHOLESTEROLAEMIA - Use of PCSK9 Inhibitors in the management of hypercholesterolaemia v5 Nov 2016.pdfHYPERCHOLESTEROLAEMIA - Use of PCSK9 Inhibitors in the management of hypercholesterolaemia v5 Nov 2016
HYPERTENSION - BP monitoring and management algorithm-v1 Sep 14.pdfHYPERTENSION - BP monitoring and management algorithm-v1 Sep 14
HYPERTENSION - Hypertension guidance-v1 Sep 2014.pdfHYPERTENSION - Hypertension guidance-v1 Sep 2014
HYPERTENSION - Traffic Light Guide to BP Measurement-v1 Sep 14.pdfHYPERTENSION - Traffic Light Guide to BP Measurement-v1 Sep 14
HYPERTRIGLYCERIDAEMIA - Guidance for the Management of Hypertriglyceridaemia 2016.pdfHYPERTRIGLYCERIDAEMIA - Guidance for the Management of Hypertriglyceridaemia 2016
LIPIDS - Lipid Management for the Primary and Secondary Prevention of Cardiovascular Disease (CVD) in Adults 2016.pdfLIPIDS - Lipid Management for the Primary and Secondary Prevention of Cardiovascular Disease (CVD) in Adults 2016
ORAL ANTICOAGULANT - Information sheet for use of single oral anticoagulant alert card across South London 2016.pdfORAL ANTICOAGULANT - Information sheet for use of single oral anticoagulant alert card across South London 2016
ORAL ANTICOAGULANT - Pan London Framework for Adult Patients Self Monitoring of INR (except ESH).pdfORAL ANTICOAGULANT - Pan London Framework for Adult Patients Self Monitoring of INR (except ESH)
ORAL ANTICOAGULANT - Self monitoring information leaflet (2) (except ESH).pdfORAL ANTICOAGULANT - Self monitoring information leaflet (2) (except ESH)
STATINS - Guidance on prescribing statins 2016.pdfSTATINS - Guidance on prescribing statins 2016
STROKE PREVENTION IN AF - (1) Pan London statement on Prevention of AF-Related Stroke June 2016 FINAL.pdfSTROKE PREVENTION IN AF - (1) Pan London statement on Prevention of AF-Related Stroke June 2016 FINAL
STROKE PREVENTION IN AF - (2) DOAC Notification of Initiation 2016.docxSTROKE PREVENTION IN AF - (2) DOAC Notification of Initiation 2016
STROKE PREVENTION IN AF - (3) DOAC Transfer of Care 2016.docxSTROKE PREVENTION IN AF - (3) DOAC Transfer of Care 2016
STROKE PREVENTION IN AF - (4) Apixaban prescribing guidance 2016.pdfSTROKE PREVENTION IN AF - (4) Apixaban prescribing guidance 2016
STROKE PREVENTION IN AF - (5) Dabigatran prescribing guidance 2016.pdfSTROKE PREVENTION IN AF - (5) Dabigatran prescribing guidance 2016
STROKE PREVENTION IN AF - (6) Edoxaban prescribing guidance 2016.pdfSTROKE PREVENTION IN AF - (6) Edoxaban prescribing guidance 2016
STROKE PREVENTION IN AF - (7)  Rivaroxaban prescribing guidance2016.pdfSTROKE PREVENTION IN AF - (7) Rivaroxaban prescribing guidance2016
Summary of antiplatelet options in cardiovascular disease final local for approval V2.pdfSummary of antiplatelet options in cardiovascular disease final local for approval V2
VTE - (1) Treatment summary for VTE Management 2016.pdfVTE - (1) Treatment summary for VTE Management 2016
VTE - (2) DOAC Notification of Initiation 2016.docxVTE - (2) DOAC Notification of Initiation 2016
VTE - (3) DOAC Transfer of Care 2016.docxVTE - (3) DOAC Transfer of Care 2016
VTE - (4) Apixaban prescribing guidance 2016.pdfVTE - (4) Apixaban prescribing guidance 2016
VTE - (5) Dabigatran prescribing guidance 2016.pdfVTE - (5) Dabigatran prescribing guidance 2016
VTE - (6) Edoxaban prescribing guidance 2016.pdfVTE - (6) Edoxaban prescribing guidance 2016
VTE - (7) Rivaroxaban prescribing guidance 2016.pdfVTE - (7) Rivaroxaban prescribing guidance 2016